Effects of Digitalis Drugs

Cardiac glycosides include digoxin, deslanoside, and strophanthin-K—three agents commonly used in clinical practice, with the first two being most frequently prescribed. So, what are the therapeutic effects of cardiac glycosides? Below is an explanation.

Therapeutic Effects of Cardiac Glycosides

Cardiac glycosides primarily enhance myocardial contractility directly, thereby increasing stroke volume. This results in reduced end-systolic residual volume and decreased end-diastolic pressure, facilitating relief of organ congestion, increased urine output, and slowed heart rate. The mechanism underlying enhanced myocardial contractility involves inhibition of the Na⁺/K⁺-ATPase pump on the cell membrane by cardiac glycosides, leading to intracellular sodium accumulation and subsequent increased calcium influx—thus augmenting myocardial contractility. Although enhanced contractility increases myocardial oxygen consumption, concomitant ventricular cavity reduction lowers wall tension, ultimately decreasing overall myocardial oxygen demand. Consequently, cardiac glycosides improve myocardial work efficiency without increasing oxygen consumption. Importantly, the therapeutic and toxic doses of cardiac glycosides are very close; therefore, patients must be closely monitored during treatment for new-onset arrhythmias or symptoms such as visual disturbances (e.g., blurred or yellow-tinted vision) and gastrointestinal complaints. Where available, serum digoxin concentration monitoring is recommended to promptly detect signs of toxicity, necessitating dose reduction or discontinuation if toxicity is suspected.

Knowledge Extension: Important Considerations When Using Cardiac Glycosides

1. Cardiac glycosides must be administered strictly under medical supervision and according to physician instructions. Patients should understand both the proper use and potential toxicity of these drugs, carefully adhering to their indications and contraindications to prevent digitalis toxicity.

2. Elderly patients with renal insufficiency, severe myocardial infarction, advanced heart failure, or significant atrioventricular (AV) conduction block require cautious use of cardiac glycosides. Additionally, concurrent administration of calcium supplements should be avoided during therapy.

3. A baseline electrocardiogram (ECG) should be obtained prior to initiating therapy, and serial ECGs should be compared before and after treatment. If electrolyte imbalances (e.g., hypokalemia or hypercalcemia) develop, cardiac glycosides must be discontinued immediately. Initial dosing should never involve large or loading doses.

The above outlines the therapeutic effects of cardiac glycosides. We hope this information is helpful to you.